COVID-19免疫治疗研究进展  

Advances in immunotherapy for COVID-19

作　　者：卢意 向明[1] Lu Yi;Xiang Ming(School of Pharmacy,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)

机构地区：[1]华中科技大学同济医学院药学院,武汉430030

出　　处：《中华微生物学和免疫学杂志》2020年第9期654-660,共7页Chinese Journal of Microbiology and Immunology

基　　金：中央高校基本科研业务费专项资金(2020kfyXGYJ038)。

摘　　要：新型冠状病毒(2019-nCoV)引起的COVID-19已经对全球公共卫生构成极大威胁。免疫系统对控制和清除2019-nCoV至关重要,但是免疫过激可加重肺组织炎性损伤及其他器官损害,而针对COVID-19免疫异常的治疗存在争议也是关注的热点。因此,本文综述了2019-nCoV感染所致的异常免疫应答及潜在的免疫治疗,以深入了解免疫调节在COVID-19中的作用,并为COVID-19的免疫治疗提供思路。COVID-19 caused by 2019-nCoV has posed a great threat to global public health.The immune system is essential for 2019-nCoV control and clearance,but excessive immune responses could result in inflammatory lung injury and other organ damages.Moreover,therapies against the abnormal immune responses to COVID-19 are controversial and of concern.This review summarized and analyzed the abnormal immune responses to 2019-nCoV infection and the potential immunotherapy,aiming to better understand the role of immunoregulation in COVID-19 and provide ideas for future research on COVID-19 immunotherapy.

关 键 词：新型冠状病毒 COVID-19 免疫异常 免疫治疗 

分 类 号：R563.1[医药卫生—呼吸系统]